Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
1,122,323
result(s) for
"DRUG THERAPY"
Sort by:
Appropriate prescribing of oral beta-lactam antibiotics
Beta-lactam antibiotics are active against many gram-negative, gram-positive and anaerobic organisms. Care must be taken when selecting a specific drug because each beta-lactam group has a somewhat different antimicrobial spectrum.
Journal Article
Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases
The human intestinal microbiota, establishing a symbiotic relationship with the host, plays a significant role for human health. It is also well known that a disease status is frequently characterized by a dysbiotic condition of the gut microbiota. A probiotic treatment can represent an alternative therapy for enteric disorders and human pathologies not apparently linked to the gastrointestinal tract. Among bifidobacteria, strains of the species Bifidobacterium breve are widely used in paediatrics. B. breve is the dominant species in the gut of breast-fed infants and it has also been isolated from human milk. It has antimicrobial activity against human pathogens, it does not possess transmissible antibiotic resistance traits, it is not cytotoxic and it has immuno-stimulating abilities. This review describes the applications of B. breve strains mainly for the prevention/treatment of paediatric pathologies. The target pathologies range from widespread gut diseases, including diarrhoea and infant colics, to celiac disease, obesity, allergic and neurological disorders. Moreover, B. breve strains are used for the prevention of side infections in preterm newborns and during antibiotic treatments or chemotherapy. With this documentation, we hope to increase knowledge on this species to boost the interest in the emerging discipline known as “therapeutic microbiology”.
Journal Article
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Background:
Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and PD-L2 on tumour cells. A phase Ib trial of P plus chemotherapy was undertaken to evaluate the safety and efficacy.
Methods:
Patients with advanced, metastatic solid tumours were enrolled onto one of six treatment arms. Pembrolizumab was given: with gemcitabine (G), G+docetaxel (D), G+nab-paclitaxel (NP), G+vinorelbine (V) or irinotecan (I) until progression or toxicity, or with liposomal doxorubicin (LD) for up to 15 cycles, progression or toxicity. Safety monitoring and response assessments were conducted.
Results:
Forty-nine patients were enrolled and treated. The most common adverse events were transaminitis, cytopenias, rash, diarrhoea, fatigue, nausea and vomiting. Arm 2 was closed due to poor accrual. The recommended phase II dose (RP2D) was determined for Arms 1, 3a, 4, 5 and 6. There were eight partial responses across multiple tumour types.
Conclusions:
Standard dose P can be safely combined with G, G+NP, G+V, I and LD. Efficacy was observed in multiple tumour types and evaluation to determine if response and duration of response are more robust than what would be expected for chemotherapy or immunotherapy alone requires further validation.
Journal Article
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
In this trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone.
Journal Article
Solution focused harm reduction : working effectively with people who misuse substances
Explains the many synergies between solution focused brief therapy (SFBT) and harm reduction (HR). Seán Foy discusses how these two approaches are complementary and when used in conjunction, create a novel way of approaching addiction work. The book covers several detailed case studies examining how the concepts and theories of both approaches are intertwined to enhance and deepen the work undertaken with people who misuse and abuse substances. It will be of great interest to scholars of psychotherapy, social work, social care, addiction, nursing and health care, as well as to practitioners seeking a clearer understanding of solution focused brief therapy and harm reduction and how to apply these to case work with problematic drinkers and drug users.
Book
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
The anti–interleukin-1 antibody canakinumab was effective at controlling and preventing recurrence of flares in autoimmune inflammatory diseases: familial Mediterranean fever, mevalonate kinase deficiency, and the TNF receptor–associated periodic syndrome.
Journal Article